A few days ago, the official website of the NMPA released the drug approval certificate. The information showed on March 22, the Lenvatinib capsule developed by Hangzhou Qingyue and Shanxiang pharmaceutical was officially approved for marketing, and was deemed to have passed the evaluation of the consistency of quality and efficacy of generic drugs. It was clinically used in the treatment of unresectable hepatocellular carcinoma.

Lenvatinib is a Multi-Targeted Oral Kinase Inhibitor. The main targets are vegfr1-4, fgfr1-3 and PDGFR α/β ，C-kit and RET, can inhibit tumor angiogenesis, inhibit tumor cell growth and regulate tumor immune microenvironment.

The results of the global multicenter reflect study show that Lenvatinib is effective in the treatment of unresectable hepatocellular carcinoma (uHCC). It has been included as the first-line drug for the treatment of advanced liver cancer in China, Japan, the United States and other countries. Especially in Chinese patients, the median overall survival time can reach 15 months, which can improve the survival time by 50%. It can be called "Chinese Customized" tumor targeted drugs.

In addition to single drug administration, in the combined treatment of target immunity, the combined treatment of Lenvatinib with immune agents such as Pembrolizumab, Nivolumab and PD-1 can further optimize the curative effect and bring various survival benefits to patients with advanced liver cancer; In addition, in the treatment of Lenvatinib combined with TACE and HAIC, that is, interventional therapy combined with system targeted therapy, it also brings more survival benefits to patients with advanced hepatocellular carcinoma in the first-line treatment.

Lenvatinib has successfully entered the new medical insurance catalogue through medical insurance negotiation in 2014, and the listing of Lenvatinib of   Shanxiang pharmaceutical is expected to further improve the drug accessibility of patients and benefit more patient groups while further activating the market vitality.